公开(公告)号：WO2017017063A3

公开(公告)日：2017-03-16

申请号：PCT/EP2016067682

申请日：2016-07-25

Applicant: MIDATECH LTD

Inventor： BARRIENTOS AFRICA GARCIA ,  DOMINGUEZ ESTHER DE TORRES

IPC: A61P35/00 ,  A61K47/54 ,  A61K47/64 ,  A61K47/68 ,  A61K47/69 ,  A61P1/16

CPC classification number: A61K47/6923 ,  A61K47/549 ,  A61K47/642 ,  A61K47/6425 ,  A61K47/6859

Abstract: The invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand; at least one payload ligand comprising a bioactive agent; and at least one dilution ligand comprising a carbohydrate. Also provided are pharmaceutical compositions comprising the nanoparticles, medical uses thereof, including in the treatment and imaging of liver cancers, and processes for the production of the nanoparticles.

Abstract translation: 本发明提供纳米粒子，其包含：包含金属和/或半导体的核心; 和多个共价连接至所述核心的配体，其中所述配体包含：至少一种肝靶向配体; 包含生物活性剂的至少一个有效负载配体; 和至少一种包含碳水化合物的稀释配体。 还提供了包含纳米颗粒的药物组合物，其医学用途，包括在肝癌的治疗和成像中，以及用于生产纳米颗粒的方法。

公开(公告)号：WO2017017063A2

公开(公告)日：2017-02-02

申请号：PCT/EP2016/067682

申请日：2016-07-25

Applicant: MIDATECH LIMITED

Inventor： BARRIENTOS, Africa, Garcia ,  DOMINGUEZ, Esther de Torres

IPC: A61P35/00

CPC classification number: A61K47/6923 ,  A61K47/549 ,  A61K47/642 ,  A61K47/6425 ,  A61K47/6859

Abstract: The invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand; at least one payload ligand comprising a bioactive agent; and at least one dilution ligand comprising a carbohydrate. Also provided are pharmaceutical compositions comprising the nanoparticles, medical uses thereof, including in the treatment and imaging of liver cancers, and processes for the production of the nanoparticles.

Abstract translation: 本发明提供一种纳米颗粒，其包括：包含金属和/或半导体的芯; 和与核共价连接的多个配体，其中所述配体包含：至少一种肝靶向配体; 至少一个有效载荷包含生物活性剂的载体; 和至少一种包含碳水化合物的稀释配体。 还提供了包含纳米颗粒的药物组合物，其医学用途，包括在肝癌的治疗和成像中以及制备纳米颗粒的方法。

公开(公告)号：WO2016202411A1

公开(公告)日：2016-12-22

申请号：PCT/EP2015/074490

申请日：2015-10-22

Applicant: UCB BIOPHARMA SPRL

Inventor： O'CONNELL, James Philip ,  PORTER, John Robert ,  LAWSON, Alastair ,  KROEPLIEN, Boris, ,  RAPECKI, Stephen Edward ,  NORMAN, Timothy John ,  MCMILLAN, David James ,  WARRELLOW, Graham John ,  BROOKINGS, Daniel Christopher ,  ALEXANDER, Rikki Peter

IPC: G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705

CPC classification number: G01N33/6863 ,  A61K47/6425 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  C07K2317/55 ,  C07K2317/92 ,  G01N33/6845 ,  G01N33/6854 ,  G01N2333/525 ,  G01N2500/02

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

Abstract translation: 本发明在TNF信号传导领域。 已经鉴定出能够通过受体调节TNF三聚体信号传导的化合物。 因此提供鉴定这些化合物的方法。 化合物本身具有治疗用途。

公开(公告)号：WO2016172153A2

公开(公告)日：2016-10-27

申请号：PCT/US2016/028365

申请日：2016-04-20

Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES ,  FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INCORPORATED

Inventor： EVANS, Ronald, M. ,  DOWNES, Michael ,  ATKINS, Annette ,  YU, Ruth, T. ,  BLABER, Michael ,  XIA, Xue

IPC: A61K38/18

CPC classification number: C07K14/503 ,  A61K38/00 ,  A61K38/1825 ,  A61K38/28 ,  A61K45/06 ,  A61K47/6425 ,  A61K48/00 ,  C07K14/50 ,  C07K14/501 ,  C07K14/705 ,  C07K2319/00 ,  C07K2319/70 ,  C07K2319/75 ,  C12N15/00 ,  C12N2015/8518 ,  C12Q1/54 ,  A61K2300/00

Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.

Abstract translation: 本公开提供了在肝素结合结构域中具有一个或多个突变的FGF1突变蛋白。 这样的突变体也可以具有N-末端缺失，点突变或其组合。 在一些实例中，突变FGF1蛋白具有降低的促有丝分裂活性。 还提供了编码这些蛋白质的核酸分子，以及包括这种核酸的载体和细胞。 所公开的FGF1突变体可以降低哺乳动物的血糖，并且在一些实例中用于治疗代谢紊乱。

公开(公告)号：WO2015160928A2

公开(公告)日：2015-10-22

申请号：PCT/US2015/025942

申请日：2015-04-15

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Inventor： ZARLING, Angela ,  ENGELHARD, Victor, H. ,  CUMMINGS, Kara, L. ,  OBENG, Rebecca, C.

IPC: A61K38/17

CPC classification number: C07K14/7051 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/19 ,  A61K39/0011 ,  A61K45/06 ,  A61K47/48276 ,  A61K47/6425 ,  A61K2039/5158 ,  A61K2039/55533 ,  C07K16/2809 ,  C07K2317/76 ,  G01N33/505 ,  G01N33/566 ,  G01N33/56977 ,  G01N33/574 ,  G01N33/57484 ,  A61K2300/00

Abstract: Provided are isolated TCRs, TCR-like molecules, and portions thereof that bind to phosphopeptide-HLA-A2 complexes. The isolated TCRs, TCR-like molecules, or portions are optionally soluble TCRs, TCR-like molecules, or portions. Also provided are isolated nucleic acids encoding the disclosed TCRs, TCR-like molecules, or portions; host cells that contain the disclosed TCRs, TCR-like molecules, or portions; pharmaceutical compositions that include the disclosed TCRs, TCR-like molecules, portions, nucleic acids, and/or T cells; kits; and methods of using the same.

Abstract translation: 提供了与磷酸肽-HLA-A2复合物结合的分离的TCR，TCR样分子及其部分。 分离的TCR，TCR样分子或部分是可选的可溶性TCR，TCR样分子或部分。 还提供了编码所公开的TCR，TCR样分子或部分的分离的核酸; 含有所公开的TCR，TCR样分子或部分的宿主细胞; 包括公开的TCR，TCR样分子，部分，核酸和/或T细胞的药物组合物; 包; 和使用它们的方法。

公开(公告)号：WO2015110809A2

公开(公告)日：2015-07-30

申请号：PCT/GB2015/050135

申请日：2015-01-21

Applicant: UCL BUSINESS PLC

Inventor： SHIMA, David ,  ANDERSON, Owen

IPC: C07K14/705

CPC classification number: C07K14/70596 ,  A61K47/64 ,  A61K47/6425 ,  C07K16/245 ,  G01N33/5308 ,  G01N33/6872 ,  G01N2333/70596 ,  G01N2400/40 ,  Y02P20/55

Abstract: The present invention concerns peptides comprising at least one motif having the amino acid sequence B 1 -X 3-10 -B 2 , wherein B 1 and B 2 arc identicial or different and each is a basic amino acid and X 3- 10 is a sequence of 3 to 10 identical or different non-acidic amino acids, and wherein the N-terminus of the peptide comprises a D-amino acid and/or includes a protecting group, collagen or hyaluronic acid conjugates comprising the same peptides and a therapeutic or diagnostic agent, and compositions and uses thereof. It also concerns peptides comprising at least one motif having the amino acid sequence B 1 -X 3-10 -B 2 , wherein B 1 and B 2 are identicial or different and each is a basic amino acid and X 3-10 is a sequence of 3 to 10 identical or different non-acidic amino acids, for use in the treatment or prevention of ocular diseases or conditions. Furthermore, it relates to a method of detecting a hyaluronic acid binding substance, the method comprising providing a sample of hyaluronic acid, contacting the sample of hyaluronic acid with a test substance, and detecting the presence of binding between the test substance and the hyaluronic acid.

Abstract translation: 本发明涉及包含至少一个具有氨基酸序列B1-X3-10-B2的基序的肽，其中B 1和B 2相同或不同，并且各自为碱性氨基酸，而X3-10为3至10个的序列 相同或不同的非酸性氨基酸，并且其中所述肽的N-末端包含D-氨基酸和/或包括保护基，包含相同肽和治疗或诊断剂的保护基，胶原或透明质酸缀合物和组合物 及其用途。 它还涉及包含至少一个具有氨基酸序列B1 -X3-10-B2的基序的肽，其中B1和B2是相同或不同的，并且各自是碱性氨基酸，X3-10是3至10个相同或相同的序列 不同的非酸性氨基酸，用于治疗或预防眼部疾病或病症。 此外，本发明涉及一种检测透明质酸结合物质的方法，该方法包括提供透明质酸样品，使透明质酸样品与检测物质接触，并检测被检物质与透明质酸之间的结合情况 。

公开(公告)号：WO2015086723A2

公开(公告)日：2015-06-18

申请号：PCT/EP2014/077314

申请日：2014-12-11

Applicant: GLYCOTOPE GMBH

Inventor： GOLETZ, Steffen ,  GOLETZ, Christoph

CPC classification number: C07K14/705 ,  A61K47/48276 ,  A61K47/6425

Abstract: The present invention pertains to glycosylated peptides of the glycophorin protein and their use in medicine. In particular, the peptides carry a carbohydrate structure of interest and are capable of binding to and being presented by MHC proteins. Using the glycosylated glycophorin peptides, a specific immune response against the carbohydrate structure of interest can be induced.

Abstract translation: 本发明涉及血型糖蛋白的糖基化肽及其在药物中的应用。 特别地，肽携带目标的碳水化合物结构，并且能够结合MHC蛋白质并由MHC蛋白质呈递。 使用糖基化血型糖蛋白肽，可以诱导针对感兴趣的碳水化合物结构的特异性免疫应答。

公开(公告)号：WO2014066487A2

公开(公告)日：2014-05-01

申请号：PCT/US2013/066353

申请日：2013-10-23

Applicant: CELGENE CORPORATION

Inventor： SUNG, Victoria ,  CHOPRA, Rajesh ,  HERMINE, Olivier ,  CRUZMOURA, Ivan ,  DUSSIOT, Michael ,  TROVATIMACIEL, Thiago ,  FRICOT, Aurelie

IPC: A61K39/395

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K47/6425 ,  C07K14/71 ,  C07K2317/76 ,  C07K2319/30

Abstract: Provided herein are methods for the treatment of anemia, wherein the methods comprise administration of antagonists of Growth differentiation factor 11 (GDFl 1; also known as bone morphogenetic protein 11 (BMP11)) to a subject in need of the treatment.

Abstract translation: 本文提供了用于治疗贫血症的方法，其中所述方法包括向需要的受试者施用生长分化因子11（GDF11;也称为骨形态发生蛋白11（BMP11））的拮抗剂 的治疗。

公开(公告)号：WO2014057043A1

公开(公告)日：2014-04-17

申请号：PCT/EP2013/071178

申请日：2013-10-10

Applicant: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN ,  ALLORPHAN UG

Inventor： STEINFELD, Robert ,  GRAPP, Marcel

IPC: A61K9/00 ,  A61K47/48 ,  G01N1/00

CPC classification number: A61K47/6425 ,  A61K9/0085 ,  A61K47/42 ,  A61K47/6907 ,  G01N33/6893

Abstract: In a first aspect, the present invention relates to a vehicle composition, in particular, to a vesicular composition or a particular composition comprising either vesicle forming components or particles, optionally, an active agent associated with the vesicle forming components or particles, and folate receptor alpha. In another aspect, the present invention relates to a delivery system for the transport of components and/or active agents into the cerebrospinal fluid (CSF) and/or brain and/or central nervous system and/or spinal cord comprising vesicles or particles and folate receptor alpha, preferably being located on the outer surface of said vesicles or particles. The present invention relates further to a method for the delivery of components and/or active agents, in particular, of active agents into the CSF and/or brain and/or central nervous system and/or spinal cord as well as for treating of CSF or brain pertaining diseases, disorders or conditions. In particular, the present invention relates to a method for preventing or treating neurological or neurodegenerative diseases, disorders or conditions, comprising administering the delivery systems or vehicle composition according to the present invention.

Abstract translation: 在第一方面，本发明涉及载体组合物，特别是涉及囊状组合物或特定组合物，其包含囊泡形成成分或颗粒，任选地，与囊泡形成成分或颗粒相关的活性剂，以及叶酸受体 α。 另一方面，本发明涉及用于将组分和/或活性剂输送到包含囊泡或颗粒和叶酸的脑脊液（CSF）和/或脑和/或中枢神经系统和/或脊髓的递送系统 受体α，优选位于所述小泡或颗粒的外表面上。 本发明还涉及将组分和/或活性剂特别是活性剂递送到CSF和/或脑和/或中枢神经系统和/或脊髓以及用于治疗CSF的方法 或脑部疾病，病症或病症。 特别地，本发明涉及一种用于预防或治疗神经性或神经退行性疾病，病症或病症的方法，包括施用根据本发明的递送系统或媒介物组合物。

公开(公告)号：WO2014031584A1

公开(公告)日：2014-02-27

申请号：PCT/US2013/055694

申请日：2013-08-20

Applicant: JANSSEN PHARMACEUTICA NV ,  ORTHO-CLINICAL DIAGNOSTICS, INC

Inventor： LIN, Ronghui ,  SALTER, Rhys ,  DECORY, Thomas R. ,  HRYHORENKO, Eric ,  REMMERIE, Bart M. ,  SANKARAN, Banumathi

IPC: C07D215/22 ,  A61K47/48 ,  C07D215/227 ,  C07D401/12 ,  G01N33/53 ,  A61K31/496 ,  A61P25/00

CPC classification number: A61K47/62 ,  A61K31/496 ,  A61K31/497 ,  A61K39/385 ,  A61K47/6425 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/6081 ,  C07D215/22 ,  C07D215/227 ,  C07D401/12 ,  C07D401/14

Abstract: The invention relates to compounds of Formula I, wherein R 1 , R 2 , and R 3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.

Abstract translation: 本发明涉及式I化合物，其中R 1，R 2和R 3在本说明书中定义，可用于合成来自阿立哌唑的新缀合物和免疫原。 本发明还涉及阿立哌唑半抗原和蛋白质的缀合物。